155 related articles for article (PubMed ID: 7589222)
1. Chronic fluoxetine or desmethylimipramine treatment alters 5-HT2 receptor mediated c-fos gene expression.
Tilakaratne N; Yang Z; Friedman E
Eur J Pharmacol; 1995 Aug; 290(3):263-6. PubMed ID: 7589222
[TBL] [Abstract][Full Text] [Related]
2. Activation and desensitization by cyclic antidepressant drugs of alpha2-autoreceptors, alpha2-heteroreceptors and 5-HT1A-autoreceptors regulating monamine synthesis in the rat brain in vivo.
Esteban S; Lladó J; Sastre-Coll A; García-Sevilla JA
Naunyn Schmiedebergs Arch Pharmacol; 1999 Aug; 360(2):135-43. PubMed ID: 10494882
[TBL] [Abstract][Full Text] [Related]
3. Fluoxetine gradually increases [125I]DOI-labelled 5-HT2A/2C receptors in the hypothalamus without changing the levels of Gq- and G11-proteins.
Li Q; Muma NA; Battaglia G; Van de Kar LD
Brain Res; 1997 Nov; 775(1-2):225-8. PubMed ID: 9439849
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase C in rat brain cortex and hippocampus: effect of repeated administration of fluoxetine and desipramine.
Mann CD; Vu TB; Hrdina PD
Br J Pharmacol; 1995 Jun; 115(4):595-600. PubMed ID: 7582477
[TBL] [Abstract][Full Text] [Related]
5. Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test.
Redrobe JP; Bourin M
Eur J Pharmacol; 1997 May; 325(2-3):129-35. PubMed ID: 9163559
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with the antidepressants fluoxetine and desipramine potentiates endocrine responses to the serotonin agonists 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) and (+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI).
Li Q; Brownfield MS; Battaglia G; Cabrera TM; Levy AD; Rittenhouse PA; van de Kar LD
J Pharmacol Exp Ther; 1993 Aug; 266(2):836-44. PubMed ID: 8394920
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study.
Beyer CE; Boikess S; Luo B; Dawson LA
J Psychopharmacol; 2002 Dec; 16(4):297-304. PubMed ID: 12503828
[TBL] [Abstract][Full Text] [Related]
8. Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, β-catenin and antidepressant-like effects.
Pilar-Cuéllar F; Vidal R; Pazos A
Br J Pharmacol; 2012 Feb; 165(4b):1046-57. PubMed ID: 21627639
[TBL] [Abstract][Full Text] [Related]
9. Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex.
Invernizzi R; Bramante M; Samanin R
Pharmacol Biochem Behav; 1996 May; 54(1):143-7. PubMed ID: 8728551
[TBL] [Abstract][Full Text] [Related]
10. Induction and maintenance of ganglionic long-term potentiation require activation of 5-hydroxytryptamine (5-HT3) receptors.
Alkadhi KA; Salgado-Commissariat D; Hogan YH; Akpaudo SB
J Physiol; 1996 Oct; 496 ( Pt 2)(Pt 2):479-89. PubMed ID: 8910231
[TBL] [Abstract][Full Text] [Related]
11. Chronic treatment with fluoxetine decreases cerebral metabolic responses to the 5-HT1A agonist 8-hydroxy-2(di-N-propylamino)tetralin and increases those to the 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and to the dopaminergic agonist apomorphine.
Freo U; Merico A; Ermani M; Ori C
Brain Res; 2010 Jun; 1335():24-34. PubMed ID: 20381465
[TBL] [Abstract][Full Text] [Related]
12. Genomic responses to 5-HT1A or 5-HT2A/2C receptor activation is differentially regulated in four regions of rat brain.
Tilakaratne N; Friedman E
Eur J Pharmacol; 1996 Jun; 307(2):211-7. PubMed ID: 8832223
[TBL] [Abstract][Full Text] [Related]
13. Regulation of 5-HT2 receptors in rat cortex. Studies with a putative selective agonist and an antagonist.
Pranzatelli MR
Biochem Pharmacol; 1991 Aug; 42(5):1099-105. PubMed ID: 1872895
[TBL] [Abstract][Full Text] [Related]
14. 5-HT receptor subtypes involved in the anxiogenic-like action and associated Fos response of acute fluoxetine treatment in rats.
Salchner P; Singewald N
Psychopharmacology (Berl); 2006 Apr; 185(3):282-8. PubMed ID: 16521035
[TBL] [Abstract][Full Text] [Related]
15. Evidence for accelerated desensitisation of 5-HT(2C) receptors following combined treatment with fluoxetine and the 5-HT(1A) receptor antagonist, WAY 100,635, in the rat.
Bristow LJ; O'Connor D; Watts R; Duxon MS; Hutson PH
Neuropharmacology; 2000 Apr; 39(7):1222-36. PubMed ID: 10760364
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical effects of lithium on serotonergic receptor function: an immunocytochemical, behavioural and autoradiographic study.
Moorman JM; Leslie RA
Neuropharmacology; 1998; 37(3):357-74. PubMed ID: 9681934
[TBL] [Abstract][Full Text] [Related]
17. Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant.
Rossby SP; Nalepa I; Huang M; Perrin C; Burt AM; Schmidt DE; Gillespie DD; Sulser F
Brain Res; 1995 Jul; 687(1-2):79-82. PubMed ID: 7583316
[TBL] [Abstract][Full Text] [Related]
18. Chronic, combined treatment with desipramine and mianserin: enhanced 5-HT1A receptor function and altered 5-HT1A/5-HT2 receptor interaction in rats.
Lund A; Mjellem N
Pharmacol Biochem Behav; 1993 Aug; 45(4):777-83. PubMed ID: 8415816
[TBL] [Abstract][Full Text] [Related]
19. Chronic fluoxetine treatment selectively uncouples raphe 5-HT(1A) receptors as measured by [(35)S]-GTP gamma S autoradiography.
Pejchal T; Foley MA; Kosofsky BE; Waeber C
Br J Pharmacol; 2002 Mar; 135(5):1115-22. PubMed ID: 11877317
[TBL] [Abstract][Full Text] [Related]
20. Lithium enhances 5-HT2A receptor-mediated c-fos expression in rat cerebral cortex.
Leslie RA; Moorman JM; Grahame-Smith DG
Neuroreport; 1993 Dec; 5(3):241-4. PubMed ID: 8298081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
